The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...

Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.

The FDA approved the enzyme replacement therapy Adzynma for the prophylactic or on-demand treatment of adults and pediatric patients with congenital thrombotic thrombocytopenic purpura, a rare blood ...

Please provide your email address to receive an email when new articles are posted on . Mean maximum ADAMTS13 activity after recombinant ADAMTS13 exceeded 100%. Markedly fewer patients receiving ...

Thanks to a Takeda approval Thursday, patients now have a drug to tackle a rare inherited blood clotting disorder. The U.S. FDA has given a green light to Takeda’s Adzynma, the first recombinant ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

Every day, Sanofi employees work to chase the miracles of science and improve people’s lives by asking themselves “what if?” Our work is rooted in scientific curiosity centered on the question: What ...

Jo McIntyre, founder of TTPNetwork and a former domestic abuse reduction coordinator, has been awarded the British Empire Medal (BEM) in the King’s New Year Honours. The award recognises her 28 years ...